Claims
- 1. A method of treating a population of enveloped viruses which comprise a glycosylphosphatidylinositol-anchored protein in their membrane, the method comprising the step of:
contacting the population of enveloped viruses with an amount of a toxin which binds to glycosylphosphatidylinositol-anchors, wherein the amount is sufficient to reduce infectivity of the population of viruses by at least 50%.
- 2. The method of claim 1 wherein the viruses are retroviruses.
- 3. The method of claim 1 wherein the viruses are HIV-1.
- 4. The method of claim 1 wherein the toxin is aerolysin.
- 5. The method of claim 1 wherein the toxin is alpha toxin of Clostridium sepficum.
- 6. The method of claim 1 wherein the toxin is enterolobin.
- 7. The method of claim 1 wherein the amount of toxin is sufficient to reduce infectivity of the population by at least 75%.
- 8. The method of claim 1 wherein the amount of toxin is sufficient to reduce infectivity of the population by at least 80%.
- 9. The method of claim 1 wherein the amount of toxin is sufficient to reduce infectivity of the population by at least 85%.
- 10. The method of claim 1 wherein the amount of toxin is sufficient to reduce infectivity of the population by at least 90%.
- 11. The method of claim 1 wherein the amount of toxin is sufficient to reduce infectivity of the population by at least 95%.
- 12. An attenuated viral vaccine, comprising:
a population of enveloped virus particles which comprise a glycosylphosphatidylinositol-anchored protein in their membranes; an oligomericed toxin bound to the glycosylphosphatidylinositol-anchored protein, wherein the infectivity of the population is reduced by at least 50% compared to a population of the enveloped virus particles without the oligomerized toxin.
- 13. The vaccine of claim 12 wherein the virus is a retrovirus.
- 14. The vaccine of claim 12 wherein the virus is HIV-1.
- 15. The vaccine of claim 12 wherein the toxin is aerolysin.
- 16. The vaccine of claim 12 wherein the toxin is alpha toxin of Clostridium septicum.
- 17. The vaccine of claim 12 wherein the toxin is enterolobin.
- 18. The vaccine of claim 12 wherein the infectivity of the virus population is reduced by at least 75%.
- 19. The vaccine of claim 12 wherein the infectivity of the virus population is reduced by at least 80%.
- 20. The vaccine of claim 12 wherein the infectivity of the virus population is reduced by at least 85%.
- 21. The vaccine of claim 12 wherein the infectivity of the virus population is reduced by at least 90%.
- 22. The vaccine of claim 12 wherein the infectivity of the virus population is reduced by at least 95%.
- 23. A method of purging a blood product, cell suspension, or tissue of enveloped viruses which comprise a glycosylphosphatidylinositol-anchored protein in their membranes, the method comprising the step of:
contacting the blood product, cell suspension, or tissue with an amount of a toxin which binds to glycosylphosphatidylinositol-anchors, wherein the amount is sufficient to bind to at least 50% of the virus present in the blood product, cell suspension, or tissue.
- 24. The method of claim 23 wherein the toxin is bound to a solid support, and after the step of contacting, the solid support and the blood product, cell suspension, or tissue are separated.
- 25. The method of claim 23 wherein the virus is a retrovirus.
- 26. The method of claim 23 wherein the virus is HIV-1.
- 27. The method of claim 23 wherein the toxin is aerolysin.
- 28. The method of claim 23 wherein the toxin is proaerolysin.
- 29. The method of claim 23 wherein the toxin is alpha-toxin of Clostridium septicum.
- 30. The method of claim 23 wherein the toxin is enterolobin.
- 31. The method of claim 23 wherein the amount of toxin is sufficient to bind to at least 75% of the virus present in the blood product, cell suspension, or tissue.
- 32. The method of claim 23 wherein the amount of toxin is sufficient to bind to at least 80% of the virus present in the blood product, cell suspension, or tissue.
- 33. The method of claim 23 wherein the amount of toxin is sufficient to bind to at least 85% of the virus present in the blood product, cell suspension, or tissue.
- 34. The method of claim 23 wherein the amount of toxin is sufficient to bind to at least 90% of the virus present in the blood product, cell suspension, or tissue.
- 35. The method of claim 23 wherein the amount of toxin is sufficient to bind to at least 95% of the virus present in the blood product, cell suspension, or tissue.
- 36. The method of claim 23 wherein the toxin renders the virus non-infective upon binding.
- 37. A method of detecting the presence of an enveloped virus in a sample, comprising the steps of:
contacting a cell-free extract of a sample with a toxin which binds to glycosylphosphatidyiinositol-anchors, whereby enveloped virus in the sample binds to the toxin; and detecting the toxin which bound to the virus, wherein the presence of toxin bound to virus indicates enveloped virus in the sample.
- 38. The method of claim 37 wherein the toxin is labeled.
- 39. The method of claim 37 wherein the toxin is bound to a solid support.
- 40. The method of claim 37 wherein the virus is a retrovirus.
- 41. The method of claim 37 wherein the virus is HIV-1.
- 42. The method of claim 37 wherein the virus is HTLV-1.
- 43. The method of claim 37 wherein the virus is SIV.
- 44. The method of claim 37 wherein the toxin is aerolysin.
- 45. The method of claim 37 wherein the toxin is proaerolysin.
- 46. The method of claim 37 wherein the toxin is alpha-toxin of Clostridium septicum.
- 47. The method of claim 37 wherein the toxin is enterolobin.
- 48. The method of claim 37 additionally comprising the step of
quantifying the toxin which is bound to virus, wherein quantity of virus-bound toxin is correlated with the quantity of the enveloped virus in the sample.
Government Interests
[0001] The U.S. Government retains certain rights in this invention due to funding as provided by grants R01AI31806 and GM07626 awarded by the National Institutes of Health.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60128541 |
Apr 1999 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09543569 |
Apr 2000 |
US |
Child |
09758248 |
Jan 2001 |
US |